The Need for Better Surrogate Parameters for Overall Survival in Colorectal Cancer

Non-operative management showed promising results for patients with mismatch repair proficient locally advanced rectal cancer, preserving organs without compromising survival.

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

The combination of encorafenib, cetuximab, and FOLFIRI showed promising antitumor activity in patients with BRAF V600E-mutant metastatic colorectal cancer.

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

Adding retifanlimab to carboplatin and paclitaxel improved progression-free survival in patients with recurrent or metastatic squamous cell carcinoma of the anal canal.

Zanidatamab combined with chemotherapy demonstrated promising antitumor activity and safety in the first-line treatment of HER2-positive mCRC, with a high response rate and manageable adverse effects.